Yes — and this is the most important thing to understand. EXOGLO Serum is a cosmetic skincare product that is already sold across Australia. It meets every safety requirement set by the Therapeutic Goods Administration. Its ingredient list is publicly registered. It has more than 950 verified customer reviews on record.

Clinical studies in cosmetics measure efficacy, not safety. Safety is established before a product is allowed onto the market. This study is asking a different question: how well does this product work, specifically for peri- and post-menopausal women in Australia? That question has never been answered with proper clinical evidence in this country. We are running the study to answer it.

We use EVE V, an AI skin imaging platform developed by EVELAB Insight. It is the same system used by Estée Lauder, Dior, Shiseido, Dr. Barbara Sturm, The Body Shop and others in their flagship clinics around the world. EVE V captures over ten skin parameters in a single scan — wrinkles, pigmentation, texture, redness, evenness, hydration, pores, elasticity — using AI models trained on millions of skin images and validated in peer-reviewed dermatology journals.

The scan itself is gentle, non-invasive, and takes about a minute. You sit in front of the device, it captures three angles, and the system generates your reading in real time. The complete visit — including the brief questionnaire — is about twenty minutes.

EVE V is certified for non-invasive skin imaging analysis. It is not a medical device, and the readings are measurements of your skin's appearance, not medical diagnoses.

Only if you specifically choose for it to be. Photograph use in marketing is a separate consent from study participation. You can participate in the full study and never have your image used in any marketing material whatsoever.

If you do choose to allow your photographs to be used, you can request that identifying features (such as eyes) are obscured. Your name will never be published without your explicit written permission, and the relationship between you and any image you appear in is yours to define.

Two reasons. The first is ethical: large cash payments can become a form of coercion, and the National Statement on Ethical Conduct in Human Research specifically asks researchers to avoid that. The second is practical: we want participants who are joining for the science and for their own skin, not for the cheque. The compensation we have chosen — a year's supply of product, plus a 30% lifetime discount — is genuinely valuable, but it self-selects for women who would actually use and value the product.

Stop using it immediately and contact the study team. We will review what has happened, document it, and provide medical advice if needed. You can withdraw from the study at any point for any reason, including a reaction — without any negative consequence and without losing any rights you would otherwise have.

The most common adverse reactions to topical skincare are mild and transient: temporary redness, dryness, or a slight tingling, usually in the first one to two weeks. These are uncommon with EXOGLO based on its post-market record, but we will be watching for them.

The scientific reason is straightforward: the integrity of monthly facial analysis depends on every scan being captured on the same equipment, under the same lighting conditions, by the same trained operator. Tiny variations in any of those factors introduce noise that obscures the signal we are trying to measure. The cleanest way to control for this in Phase 1 is to bring everyone into a single clinic.

Phase 2 of the study will use a validated decentralised assessment kit — a controlled-light hood and standardised capture protocol that we can ship to participants in other cities. We are working on it now. If you are outside Sydney and would like to be considered for Phase 2, please join the research register above. We will write to you before Phase 2 opens to the public.

Mostly, yes — but with some restrictions. You will need to discontinue any other facial cosmetic actives (other serums, retinoids, vitamin C serums, exfoliants, growth-factor or exosome products) during the 12-week study period, because we need to be able to measure what EXOGLO is doing without confounding inputs. You can and should continue with: a gentle cleanser, a bland moisturiser, and broad-spectrum SPF 30+ sunscreen daily. Stable systemic medication, including menopausal hormone therapy, is fine to continue.

Three things. First, you receive your personalised skin-health report. Second, your full year's supply of EXOGLO ships to you. Third, the aggregated, de-identified data is analysed, written up, and submitted to a peer-reviewed dermatology journal. You will be the first to know when it is published — and, if you've opted in, your contribution will be acknowledged.

The Principal Investigator (Dr Joshua Chou) and the study coordinator review every application. Acceptance is based on eligibility, fit with the cohort we are trying to build (which fairly represents both peri- and post-menopausal sub-groups), and ability to commit to the full twelve weeks. It is not first-come-first-served.

If you are not accepted, you may still hear from us about future research. With your permission, we keep applicant details on a research register.